Guardant Health stock: 48 percent growth, a $112 million quarterly loss — and a federal billing investigation since April 2026

There is an investor trap that is especially cruel because it feels like decency: the halo trap. It works like this. A company plainly does something good — it finds cancer before it hurts — and your brain quietly switches from "is this a good business?" to "who wants to be the cynic here?" The numbers become a detail because the mission is so large. Guardant Health, Inc. (NASDAQ: GH) of Palo Alto, California is the hardest test case for that trap. The company sells blood tests that search for traces of tumor DNA in the bloodstream. Its Shield test is, according to the quarterly report, the first blood test approved by the U.S. Food and Drug Administration for primary colorectal cancer screening. That is not a marketing line; it is written into a filing with the U.S. securities regulator, the SEC. So let us make a deal: we admire the medicine — and then we read together what the annual report (10-K) for 2025 and the quarterly report (10-Q) as of March 31, 2026 say about the business behind it. An SEC filing is honest under penalty of law. And this one tells a story of 48 percent growth, of a $112.1 million quarterly loss, of equity that has been used up — and of a federal prosecutor who has been asking for billing records since April 22, 2026.

What this analysis covers

• What Guardant Health actually does
• How the stock landed on our desk
• The numbers over the years — honestly credited
• What the filings say — the uncomfortable truths
• What the market is charging for it
• Opportunities and risks at a glance
• A human conclusion
• Sources

What Guardant Health actually does — a vial of blood instead of a tissue sample

The everyday picture is quickly told. To find out which mutations drive a tumor, you used to need a piece of the tumor — surgery, or a needle through the skin. Guardant sells the shortcut: a vial of blood. Dying tumor cells shed tiny fragments of their DNA into the bloodstream. Anyone who can sort those fragments can read the tumor without touching it. The technical term is liquid biopsy — a tissue sample without the tissue.

Four product families have grown out of that idea. Guardant360 is the original: it looks for targets for precision drugs in patients with advanced cancer, and the Guardant360 CDx version is, per the filing, the first comprehensive liquid biopsy approved by the FDA for tumor mutation profiling. Guardant Reveal answers the question that follows surgery: is there tumor left that nobody can see? Shield is screening for healthy people — a blood test for colorectal cancer aimed at average-risk adults aged 45 and older, and it is included in the colorectal cancer screening guidelines of the National Comprehensive Cancer Network. And GuardantINFORM sells curated data to pharmaceutical companies for their drug development.

In the books that turns into four revenue sources. For full-year 2025: oncology, $683.6 million; biopharma and data, $210.1 million; screening, $79.7 million; and licensing and other, $8.6 million — $982.0 million in total. As of December 31, 2025 the company employed 2,506 people, 2,490 of them full-time and roughly 2,278 in the United States. It is run by two co-chief executive officers, Helmy Eltoukhy and AmirAli Talasaz, and reports as a single operating segment.

And that names the central tension of this analysis, which runs through every chapter that follows: Guardant\'s growth does not hang on the laboratory but on a reimbursement decision. Whoever pays for the test decides whether it sells — and since April 22, 2026 that same payer is the one whose prosecutors are examining the billing.

How the stock landed on our desk — rank 21 in the weekly list

Guardant Health did not reach us through a press release but through a ranking produced by our in-house stock scanner. In the list Richard Moglen: 1 Week Top Performers (U.S. selection) the stock sat at rank 21 of 28, with a relative strength rating of 92 out of 100, as of July 25, 2026. That list is recomputed daily — the placement is a snapshot of that day, not a permanent state. To reproduce it: the ranking is openly available in the scanner overview and sorts by price performance over the past trading week.

The three conditions behind the list, translated and judged. At least 15 percent price gain over four trading days — a pure momentum criterion; it says something about demand for the shares that week, nothing about the company. Average daily dollar volume of at least $10 million — this filter keeps out securities you may not be able to exit; Guardant clears it easily at roughly $409 million (data as of July 26, 2026), which is real liquidity. A relative strength rating of at least 70 — the measure compares a share price against the broad market on a scale to 100. A reading of 92 means only 8 percent of tracked stocks did better. Impressive — and also the only thing on this list you can have without opening the books. Remember the sentence right at the start: a momentum scanner finds movement, not quality. So into the books we go.

The numbers over the years — honestly credited

First what genuinely impresses, and there is plenty of it. Revenue has nearly tripled in five years: from $373.7 million in 2021 to $982.0 million in 2025, a gain of 33 percent in 2025 alone. And the pace did not fade afterwards, it picked up: revenue rose 48 percent to $301.7 million in the first quarter of 2026. If you wonder how often a billion-dollar company manages that, the honest answer is: rarely.

The driver has a name: Shield. Screening was still a rounding error in 2024 at $5.1 million, brought in $79.7 million in 2025 from roughly 87,000 tests — and then came the first quarter of 2026. The filing puts it plainly:

"Screening revenue was $41.6 million for the three months ended March 31, 2026, compared to $5.7 million for the three months ended March 31, 2025, an increase of $35.9 million, or 633%. The increase was driven primarily by an increase in our Shield screening test volume to approximately 44,000 for the three months ended March 31, 2026 from approximately 9,000 for the three months ended March 31, 2025."

— Guardant Health, Inc., Form 10-Q as of March 31, 2026, "Comparison of the Three Months Ended March 31, 2026 and 2025"

Do the arithmetic: $41.6 million across roughly 44,000 tests works out to just under $950 per test — our own calculation from the figures in the quarterly report. The oncology core did not stall either: $205.0 million in the first quarter of 2026, up 36 percent, on roughly 86,000 tests against roughly 59,000 a year earlier. The gross margin — the share of revenue left after the pure laboratory cost — held at a solid 65 percent in the first quarter of 2026 ($196.7 million of $301.7 million). For a laboratory running sequencers and reagents, that is a respectable number. If you want to see how another supplier in the genomics business handles persistent losses, the comparison is in our analysis of Twist Bioscience.

What the filings say — the uncomfortable truths

Uncomfortable truth No. 1: one payer accounts for 27 percent of revenue

Guardant does not name its largest customers; it calls them "Customer A" and "Customer B." What the filing does say: a significant customer is any biopharmaceutical customer, clinical testing payer or international laboratory partner that represents 10 percent or more of revenue or of receivables. The table underneath is blunt.

Across full years the dependence is documented even further back: 28 percent in 2025, 29 percent in 2024, 31 percent in 2023. The annual report adds a second line in the open: "Revenue attributable to Medicare accounted for more than 10% of our total revenue in each of the years ended December 31, 2025, 2024 and 2023." What does that mean day to day? A single reimbursement decision can move a quarter of the business. When Medicare brought Shield into coverage in August 2024 and granted ADLT status in March 2025 — a special rule for novel laboratory tests that allows a separate, market-based price — the result within eighteen months was a business generating $41.6 million of quarterly revenue. The same mechanism runs in reverse.

Uncomfortable truth No. 2: since April 22, 2026 a prosecutor has been examining exactly that billing

This line was not in the annual report of February 19, 2026. It appears for the first time in the quarterly report of May 7, 2026, in Note 9 under the unremarkable heading "Other Legal Matters":

"On April 22, 2026, the Company received a civil investigative demand, or CID, from the United States Attorney for the Southern District of Florida in connection with an investigation under the False Claims Act. The CID requests information and documents regarding billing to federally funded health insurance programs. The Company is fully cooperating with the investigation. At this time, the Company is unable to predict the outcome of this investigation."

— Guardant Health, Inc., Form 10-Q as of March 31, 2026, Note 9 "Other Legal Matters"

For context, without drama: a civil investigative demand is neither a verdict nor a charge; it is a request to produce documents. The False Claims Act, however, is no minor statute — it is the sharpest tool the United States has against fraudulent billing of government programs, and on conviction it provides for treble damages plus per-claim penalties. Guardant has recorded no accrual and named no order of magnitude. That is exactly the point: this exposure cannot be quantified today, neither upward nor downward. It sits in the filing, it is open, and it touches the artery carrying a quarter of revenue.

Uncomfortable truth No. 3: equity has been used up

Look at the balance sheet as of March 31, 2026 — at the heading, not the numbers. It does not read "Stockholders\' Equity" but "Stockholders\' Deficit." That is not stylistic whim: total liabilities of $2,096.4 million exceed total assets of $1,915.3 million. What is left is a deficit of $181.1 million. At the end of 2021 the same line still showed positive $645.0 million.

The reason is in the filing too, and it is no accounting trick but simply the sum of every loss since inception:

"We have incurred losses and negative cash flows from operations since our inception, and as of March 31, 2026, we had an accumulated deficit of $3.1 billion. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to invest in clinical studies and develop new products, expand our sales organization, and increase our marketing efforts to drive market adoption of our tests."

— Guardant Health, Inc., Form 10-Q as of March 31, 2026, "Liquidity and capital resources"

Fairness demands the other side. There is no going concern warning in the filing. On the contrary, Guardant states that its resources are sufficient for more than twelve months. The cash box is genuinely full: $989.3 million in cash and equivalents plus $113.5 million in short-term marketable securities as of March 31, 2026, or $1,102.8 million together; including restricted cash the filing arrives at roughly $1.2 billion. At the first quarter\'s free cash outflow of $71.2 million that lasts roughly 15 quarters on paper. The money did not come from the business, though, but from the capital market: in November 2025 the company placed 2,856,981 new shares and 976,351 treasury shares at $90.00 each and netted $327.3 million.

Uncomfortable truth No. 4: $1.49 billion of convertible notes — and the first tranche matures in 2027

A convertible note is a loan with a share voucher built in: the buyer lends money and may later swap it for stock if the price has risen far enough. Guardant has three of them outstanding, $1,493.2 million of principal in total:

• 2027 notes, $490.7 million, zero percent interest, maturing November 15, 2027, conversion price roughly $139.82 per share.
• 2031 notes, $600.0 million, 1.25 percent interest, maturing February 15, 2031, conversion price roughly $62.22. These met the price condition during the first quarter of 2026 and were therefore convertible from April 1 to June 30, 2026; as of May 1, 2026 the filing reports that no conversion notices had been received.
• 2033 notes, $402.5 million, zero percent interest, issued in November 2025, maturing May 15, 2033, conversion price roughly $121.50.

Two things matter here. First, the date: the 2027 notes of $490.7 million come due in a little over a year — against $1,102.8 million of cash and securities that is payable, but it is a real payment, not an accounting entry. Second, the dilution — your slice of the pie gets smaller when new slices are handed out. The filing does the math itself: 28.466 million potential additional shares were excluded from diluted loss per share, 16.465 million of them from the convertible notes. Against the 131.273 million weighted-average shares of the quarter that is roughly 22 percent. On top of that, 32,075,509 shares were reserved for employee programs as of March 31, 2026, and an at-the-market program of up to $400.0 million sits ready, from which no share had been sold by that date.

Uncomfortable truth No. 5: sales is growing faster than revenue

This is the line on which the whole question of eventual profitability turns. Revenue rose 48 percent in the first quarter of 2026 — sales and marketing expense rose 62 percent to $169.1 million. That is 56 percent of revenue: for every dollar sold, more than half a dollar goes into selling it. Add research and development of $91.0 million and general and administrative expense of $57.9 million. In total, a gross profit of $196.7 million faced operating costs of $318.1 million — and the $121.4 million gap is exactly the quarter\'s operating loss.

None of that is wrong in itself: a screening test does not sell itself, primary care physicians have to know it and order it. But it makes the calculation investors must run very concrete: for this company to turn a profit, either the price per test has to rise or sales spending has to stop growing. A third cost block runs quietly alongside: stock-based compensation was $47.6 million in the first quarter of 2026 and $166.2 million for full-year 2025 — roughly 17 percent of annual revenue, paid not in cash but in ownership. For a profitable counterexample from the laboratory business, see our analysis of Bio-Techne.

What the market is charging for it

A price-earnings ratio cannot be formed — there are no earnings. That leaves the price-to-sales ratio, which sets market value against annual revenue and answers the question of how many years of sales the market is paying for today. At a market value of roughly $19.5 billion (as of July 26, 2026, based on the closing price of July 24, 2026) and trailing twelve-month revenue of roughly $1.08 billion, that works out to about 18 times; measured against fiscal 2025 it is just under 20 times. Adding the notes and deducting cash changes little: enterprise value also lands at roughly 18 times trailing revenue.

For context, and without turning it into a buy argument: 18 times revenue is what you normally pay for software with 80 percent margins and recurring contracts — not for a laboratory with a 65 percent gross margin that loses money every year. The price therefore already contains the assumption that Shield scales into the millions of tests. One cross-check that supports the point: market value equals roughly ten times every asset on the balance sheet ($1.92 billion as of March 31, 2026).

How the professionals see it: 23 analysts covered the stock as of July 26, 2026 — 18 at the highest buy rating, 4 at buy, none at hold and one at sell; the average price target was around $171. That is a remarkably unanimous picture, and precisely for that reason it deserves one sentence of caution: a consensus of 22 to 1 has little friction built in. For the current year, incidentally, those same estimates still expect a loss per share.

Opportunities and risks at a glance

What speaks for Guardant Health:

• Shield is, per the quarterly report, the first blood test approved by the FDA for primary colorectal cancer screening and the first to meet Medicare\'s coverage requirements — a head start a rival cannot close overnight.
• Growth is accelerating rather than flattening: up 33 percent in 2025, up 48 percent in the first quarter of 2026, and screening alone reached half of the entire prior-year volume in that one quarter with roughly 44,000 tests.
• The 65 percent gross margin in the first quarter of 2026 shows that each additional test genuinely contributes — scaling does not fail in the laboratory.
• With $1,102.8 million in cash and short-term securities as of March 31, 2026 the company is funded for years, and there is expressly no going concern warning.
• A won lawsuit against rival Natera worth $287.0 million (affirmed July 28, 2025) sits out there as a possible cash inflow without appearing on the balance sheet.

What speaks against it:

• No profit in any year since the 2018 IPO; the accumulated deficit is $3.1 billion and equity is used up at negative $181.1 million.
• A single payer accounts for 27 percent of quarterly revenue — one reimbursement decision can move a quarter of the business, in either direction.
• The civil investigative demand of April 22, 2026 under the False Claims Act targets exactly that billing; Guardant says it cannot predict the outcome and has recorded no accrual.
• Roughly 22 percent of potential dilution from convertible notes and employee programs; the 2027 note of $490.7 million matures on November 15, 2027.
• Sales is growing faster than revenue (up 62 versus up 48 percent in the first quarter of 2026) — which lengthens the road to profit rather than shortening it.
• A price-to-sales ratio of roughly 18 leaves little room for disappointment, and the competition is well staffed: Foundation Medicine (Roche), Exact Sciences, Natera, Tempus AI, Caris, Quest and LabCorp are named in the annual report.

A human conclusion

Back to the halo trap from the opening. It is stubborn because both halves are true: a blood test that finds colorectal cancer before anyone has symptoms is a good thing — and a company with a $3.1 billion accumulated deficit, used-up equity and an open billing investigation is a risky investment. Neither refutes the other. You are allowed to hold both thoughts at once, and whoever does not ends up buying a mission instead of a stock.

What is documented: revenue rose 48 percent in the first quarter of 2026, screening grew 633 percent, the gross margin holds at 65 percent, and $1.1 billion sits in the bank. Equally documented: not one profitable year since inception, equity gone, a quarter of revenue hanging on a single payer — and since April 22, 2026 a federal prosecutor wants to see the invoices sent to that very payer. The price today pays roughly 18 times a year of revenue, and therefore pays for a future in which both of those stories end well.

We are not going to tell you whether to buy this stock. We will tell you which three numbers carry the answer: the revenue share of the largest payer, the gap between gross profit and operating costs — and the next line in Note 9. What you make of that is your decision. And that is exactly as it should be.

Sources

• Guardant Health, Inc. — Form 10-Q as of March 31, 2026 (filed May 7, 2026, accession 0001576280-26-000026)
• Guardant Health, Inc. — Form 10-K for 2025 (filed February 19, 2026, accession 0001576280-26-000013)
• Guardant Health, Inc. — Form 10-K for 2024 (filed February 20, 2025, accession 0001576280-25-000044)
• Guardant Health, Inc. — Form 8-K of May 7, 2026 (Item 2.02, quarterly results)
• All SEC filings of Guardant Health, Inc. (CIK 0001576280) on EDGAR
• Fundamental data (metrics, quarterly series, analyst estimates), as of July 26, 2026, based on the closing price of July 24, 2026

This analysis is journalistic commentary and expressly not investment advice, not a buy or sell recommendation and not a solicitation to buy or sell securities. All figures come from the primary sources linked above and were verified on July 26, 2026; later developments are not reflected. Shares can lose substantial value, and a total loss of invested capital is possible. The author holds no position in Guardant Health, Inc. at the time of publication.